Virus. When you hear the word, you probably shudder. But not all viruses are bad or cause disease. Some are even used for ...

Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, late-stage biotechnology company advancing a sustainable pipeline of genetic therapies for rare disorders with high unmet need, today ...

Researchers spot new campaign that can turn off antivirus protection Malware uses legitimate Avast Anti-Rootkit driver to ...

The patient died from complications linked to a rare hyperinflammatory syndrome associated with exposure to high doses of the AAV therapy delivery vehicle.

This research evaluates the effects of various gene therapy viral vectors on RPE cells to determine efficacy for therapeutic ...

According to Alnylam’s Tim Mooney, mivelsiran’s endurance is due to stabilizing tweaks the scientists made to the siRNA ...

A patient has died after receiving the high dose of Neurogene’s Rett syndro | A patient has died after receiving the high ...

OXB to host a free webinar on accelerating development of viral vectors through automated manufacturing and analytical ...

A serious adverse event in the New York biotech’s phase 1/2 trial of its Rett syndrome gene therapy puts a question mark over ...

SRD-001/2/3 employ an adeno-associated virus (AAV)-based vector system, delivered directly to cardiac ventricular muscle cells via Sardocor’s proprietary intracoronary infusion system. Furthermore, ...

Siren Biotechnology's Approach Could Transform the High-Grade Glioma Therapy Landscape "SRN-101 has the potential to address ...

Following this update, the company's stock price dropped more than 30 percent from market close Friday to $23.79 per share Monday morning.